Finally, to assess rituximab’s ability to enter collagen spheroid co-cultures and subsequently target the DLBCL cells within them, we assessed levels of two molecules expressed by DLBCL cells that interact with rituximab, its target molecule CD20 and the inhibitory FcγRIIB (CD32B) able to bind rituximab’s Fc region (30). Here, FCGR2B is linked to diffuse large B-cell lymphoma.